The influence of heart disease on characteristics, quality of life, use of health resources, and costs of COPD in primary care settings

BMC Cardiovascular Disorders

Volumn 10, Issue , 2010, Pages

  de Miguel Díez, Javier ^a   Carrasco Garrido, Pilar ^b   Rejas Gutierrez, Javier ^c   Martín Centeno, Antonio ^c   Gobartt Vázquez, Elena ^d   Hernandez Barrera, Valentín ^b   de Miguel, Angel G ^b   Jimenez Garcia, Rodrigo ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

^c PFIZER INC   (United States)

^d Health Economics and Outcomes Research   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; INFLUENZA VACCINE; MUCOLYTIC AGENT; PNEUMOCOCCUS VACCINE; STEROID; THEOPHYLLINE;

AGED; ANXIETY; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; EXERCISE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART DISEASE; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PNEUMOCOCCAL INFECTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SMOKING; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; COST OF ILLNESS; ECONOMICS; HEALTH CARE PLANNING; MIDDLE AGED; MULTICENTER STUDY; PRIMARY HEALTH CARE; UTILIZATION REVIEW;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COST OF ILLNESS; FEMALE; HEALTH RESOURCES; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE;

EID: 77949542544     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-10-8     Document Type: Article

References (48)

1. Peces-Barba G, Barberà JA, Agustí A, Casanova C, Casas A, Izquierdo JL, et al. Guía clínica SEPAR-ALAT de diagnóstico y tratamiento de la EPOC. Arch Bronconeumol 2008, 44:271-281. 10.1157/13119943, 18448019.
2. Sobradillo Peña V, Miravitlles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Fernando Masa J, et al. Geographic variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 2000, 118:981-989. 10.1378/chest.118.4.981, 11035667.
3. Menezes AM, Pérez-Padilla R, Jardim JR, Muino A, López MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005, 366:1875-1881. 10.1016/S0140-6736(05)67632-5, 16310554.
4. Sydney S, Sorel M, Quesemberry CP, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care. Chest 2005, 128:2068-2075. 10.1378/chest.128.4.2068, 16236856.
5. Holgin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the US, 1979 to 2001. Chest 2005, 128:2005-2011. 10.1378/chest.128.4.2005, 16236848.
6. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005, 128:2640-2646. 10.1378/chest.128.4.2640, 16236937.
7. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risk in men and women from the Renfrew and Paisley prospective population study. BMJ 1996, 313:711-715. 2352103, 8819439.
8. Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000, 343:1902-1909. 10.1056/NEJM200012283432601, 11136260, Lung Health Study Research Group.
9. Villar Alvarez F, de Miguel Díez J, Álvarez-Sala JL. EPOC y acontecimientos cardiovasculares. Arch Bronconeumol 2008, 44:152-159.
10. Lusuardi M, Garuti G, Massobrio M, Spagnolatti L, Bendinelli S. Heart and lungs in COPD. Close friends in real life--separate in daily medical practice?. Monaldi Arch Chest Dis 2008, 69:11-17.
11. Herland K, Akselsen J, Skjonsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?. Respir Med 2005, 99:11-19. 10.1016/j.rmed.2004.03.026, 15672843.
12. Carrasco Garrido P, de Miguel Díez J, Rejas Gutiérrez J, Martín Centeno A, Gobartt Vázquez E, Gil de Miguel A, García Carballo M, Jiménez García R. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes 2006, 4:31. 10.1186/1477-7525-4-31, 1488827, 16719899.
13. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest 2001, 119:1691-1695. 10.1378/chest.119.6.1691, 11399692.
14. Barberà JA, Peces-Barba G, Agustí AGN, Izquierdo JL, Monsó E, Montemayor T, Viejo JL, . Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR) Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica. Arch Bronconeumol 2001, 37:297-316. Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR).
15. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
16. Ware JE, Kosinski M, Keller SD. A 12-item short-form health survey. Construction of scales and preliminary tests of realiabity and validity. Med Care 1996, 34:220-233. 10.1097/00005650-199603000-00003, 8628042.
17. Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, et al. El cuestionario de salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit 2005, 19:135-150. 10.1157/13074369, 15860162.
18. Vilagut G, Ferrer M, Rajmil L, Rebollo P, Permanyer-Miralda G, Quintana JM, et al. El cuestionario de salud SF-36 español: una década de experiencia y nuevos desarrollos. Gac Sanit 2005, 19:135-150. 10.1157/13074369, 15860162.
19. Instituto Nacional de Estadística 2003 Base de datos tempus. Resultados de 1999. [citado Dic. 2003]., Instituto Nacional de Estadística 2003., http://www.ine.es
20. Van Manen JG, Bindels PJ, IJzermans CJ, Zee JS, Bottema BJ, Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol 2001, 54:287-293. 10.1016/S0895-4356(01)00346-8, 11223326.
21. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization. Arch Intern Med 2000, 160:2653-2658. 10.1001/archinte.160.17.2653, 10999980.
22. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005, 128:2099-2107. 10.1378/chest.128.4.2099, 16236861.
23. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E, She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006, 16:63-70. 10.1016/j.annepidem.2005.04.008, 16039877.
24. Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, Diaz P. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008, 5:543-548. 10.1513/pats.200708-142ET, 2645333, 18453369.
25. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003, 107:1514-1519. 10.1161/01.CIR.0000056767.69054.B3, 12654609.
26. Antonelli-Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997, 10:2794-2800. 10.1183/09031936.97.10122794, 9493663.
27. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low-grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000, 321:199-204. 10.1136/bmj.321.7255.199, 27435, 10903648.
28. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115-126. 10.1056/NEJM199901143400207, 9887164.
29. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363-369. 10.1161/01.CIR.0000053730.47739.3C, 12551853.
30. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6. Thromb Haemost 2000, 84:210-215.
31. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006, 61:17-22. 10.1136/thx.2005.041996, 2080712, 16055618.
32. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006, 61:23-28. 10.1136/thx.2005.042200, 2080714, 16143583.
33. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:250-255. 10.1164/rccm.200605-713OC, 17053205.
34. De Torres JP, Cordoba-Lanus E, López-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006, 27:902-907.
35. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation 1999, 100:96-102.
36. Salpeter S, Ormiston T, Salpeter E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004, 125:2309-2321. 10.1378/chest.125.6.2309, 15189956.
37. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, . TORCH Investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789. 10.1056/NEJMoa063070, 17314337, TORCH Investigators.
38. Huerta C, Lanes SF, Garcia Rodriguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005, 16:360-366. 10.1097/01.ede.0000158743.90664.a7, 15824553.
39. Hooft CS, Heeringa J, Brusselle GG, Hofman A, Witteman JC, Kingma JH, Sturkenboom MC, Stricker BH. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006, 166:1016-1020. 10.1001/archinte.166.9.1016, 16682576.
40. Ferrer M, Alonso J, Morera J, Marrades RM, Khalaf A, Aguar MC, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997, 127:1072-1079.
41. Van Manen JG, Bindels PJ, Dekker EW, Ijzermans CJ, Bottema BJ, Zee JS, et al. Added value of co-morbidity in predicting health-related quality of life in COPD patients. Respir Med 2001, 95:496-504. 10.1053/rmed.2001.1077, 11421508.
42. Oostenbrink J, Rutten-van Molken M. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 2004, 98:883-91. 10.1016/j.rmed.2004.02.013, 15338802.
43. Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006, 27:627-643. 10.1183/09031936.06.00024605, 16507865.
44. Yeo Y, Karimova G, Bansal S. Co-morbidity in older patients with COPD - its impacto on health service utilisation and quality of life, a community study. Age and Ageing 2006, 35:33-37. 10.1093/ageing/afj002, 16364931.
45. De Miguel Díez J, Carrasco Garrido P, García Carballo M, Gil de Miguel A, Rejas Gutierrez J, Bellón Cano JM, et al. Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulmon Dis 2008, 3:701-712. 2650614, 19281084.
46. Sicras Mainar A, Navarro Artieda R, Fernández de Bobadilla J, García Vargas M. Estimation of the presence of cardiovascular events and direct costs associated with chronic obstructive pulmonary disease in an ambulatory setting. Med Clin (Barc) 2007, 128:317-8. 10.1016/S0025-7753(07)72573-3, 17338867.
47. Marco JL, Martin Berra JC, Corres IM, Luque DR, Zubillaga GG. [Chronic obstructive lung disease in the general population. An epidemiologic study performed in Guipuzcoa]. Spanish. ArchBronconeumol 1998, 34:23-27.
48. Brotons B, Perez JA, Sanchez-Toril F, Soriano S, Hernandez J, Belenguer JL. [The prevalence of chronic obstructive pulmonary disease and asthma. A cross-sectional study]. Spanish. Arch Bronconeumol 1994, 30:149-152.